Player FM - Internet Radio Done Right
Checked 2M ago
הוסף לפני three שנים
תוכן מסופק על ידי Talking About Tumors. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי Talking About Tumors או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
Player FM - אפליקציית פודקאסט
התחל במצב לא מקוון עם האפליקציה Player FM !
התחל במצב לא מקוון עם האפליקציה Player FM !
פודקאסטים ששווה להאזין
בחסות
L
Lipstick on the Rim
![Lipstick on the Rim podcast artwork](https://cdn.player.fm/images/36353102/series/xCZoNvzVfGikvCeg/32.jpg 32w, https://cdn.player.fm/images/36353102/series/xCZoNvzVfGikvCeg/64.jpg 64w, https://cdn.player.fm/images/36353102/series/xCZoNvzVfGikvCeg/128.jpg 128w, https://cdn.player.fm/images/36353102/series/xCZoNvzVfGikvCeg/256.jpg 256w, https://cdn.player.fm/images/36353102/series/xCZoNvzVfGikvCeg/512.jpg 512w)
![Lipstick on the Rim podcast artwork](/static/images/64pixel.png)
1 Amy Schumer & Brianne Howey on the Importance of Female Friendships, Navigating Hollywood's Double Standards, Sharing Their Birth Stories, and MORE 50:05
50:05
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי50:05![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
This week, in what might be the funniest episode yet, Molly and Emese are joined by co-stars Amy Schumer and Brianne Howey. They get candid about motherhood, career evolution, and their new film, Kinda Pregnant —which unexpectedly led to Amy’s latest health discovery. Amy opens up about how public criticism led her to uncover her Cushing syndrome diagnosis, what it’s like to navigate comedy and Hollywood as a mom, and the importance of sharing birth stories without shame. Brianne shares how becoming a mother has shifted her perspective on work, how Ginny & Georgia ’s Georgia Miller compares to real-life parenting, and the power of female friendships in the industry. We also go behind the scenes of their new Netflix film, Kinda Pregnant —how Molly first got the script, why Amy and Brianne were drawn to the project, and what it means for women today. Plus, they reflect on their early career struggles, the moment they knew they “made it,” and how motherhood has reshaped their ambitions. From career highs to personal challenges, this episode is raw, funny, and packed with insights. Mentioned in the Episode: Kinda Pregnant Ginny & Georgia Meerkat 30 Rock Last Comic Standing Charlie Sheen Roast Inside Amy Schumer Amy Schumer on the Howard Stern Show Trainwreck Life & Beth Expecting Amy 45RPM Clothing Brand A Sony Music Entertainment production. Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Learn more about your ad choices. Visit podcastchoices.com/adchoices…
Introduction (Updated 12.17.23)
Manage episode 324500959 series 3335024
תוכן מסופק על ידי Talking About Tumors. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי Talking About Tumors או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
Overview of our podcast and goal.
49 פרקים
Introduction (Updated 12.17.23)
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 324500959 series 3335024
תוכן מסופק על ידי Talking About Tumors. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי Talking About Tumors או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
Overview of our podcast and goal.
49 פרקים
Alle episoder
×1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Finn RS, et al. Oncologist . 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183 2. Pfister D et al. Nature 2021 592:7854 . 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0 3. Zhu AX et al. Lancet Oncol . 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9 4. Abou-Alfa GK, et al. NEJM Evidence . 2022;1(8). doi:10.1056/EVIDOA2100070 5. Kudo M, et al. Lancet . 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 7. Llovet JM, et al. NEJM . 2008;359(4):378-390. doi:10.1056/NEJMOA0708857 8. Reig M, et al.. J Hepatol . 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018 9. Cheng AL et al. J Hepatol . 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 10. Finn RS et al. NEJM . 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/ 11. Rose S, et al. Lancet . 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Pico JL et al. Ann Oncol . 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228 2. Adra N, et al. J Clin Oncol . 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395 3. Nichols CR et al. J Clin Oncol . 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287 4. de Wit R et al.. JCO . 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837 5. Culine S, et al. Ann Oncol . 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062 6. Lorch A, et al. Journal of Clinical Oncology . 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086 7. Fung C, et al.. J Natl Compr Canc Netw . 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Hiester A et al. Eur J Cancer . 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022 2. Calaway AC et al. Eur Urol . 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031 3. Oliver RTD et al. J Clin Oncol . 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655 4. Oliver RTD et al. Lancet . 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X 5. Joffe JK et al. J CO . 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/ 6. Bhatia S et al.. J NCCN . 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040 7. Stephenson A et al. J Urol . 2019;202(2):272-281. doi:10.1097/JU.0000000000000318 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_08 Metastatic Renal Cell Carcinoma 24:16
24:16
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי24:16![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545 Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675 Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044 Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714 Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501 Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023 Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126 Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716 Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090 Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_07 Localized Renal Cell Carcinoma 25:15
25:15
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי25:15![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Risk Factors and Presentation 2. Staging and Paraneoplastic syndromes 3. Localized Therapy Options and Considerations 4. Evidence and Limitations for Adjuvant Systemic Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology . 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG 2. Ravaud A et al. NEJM . 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/ 3. Pal SK et al. Lancet . 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0 4. Motzer RJ et al. Lancet . 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0 5. Correa AF et al. Eur Urol . 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025 6. Choueiri TK et al. NEJM . 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/ 7. Choueiri TK et al. NEJM . 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_06 Metastatic Urothelial Cancer 24:33
24:33
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי24:33![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Powles T et al. NEJM . 2024;390(10):875-888. doi:10.1056/NEJMOA2312117/ 2. Powles T et al. NEJM . 2020;383(13):1218-1230. doi:10.1056/NEJMOA2002788/ 3. Galsky MD et al. Lancet . 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0 4. Powles T et al. Lancet Oncol . 2021;22(7):931-945. doi:10.1016/S1470-2045(21)00152-2 5. van der Heijden MS et al. NEJM . 2023;389(19):1778-1789. doi:10.1056/NEJMOA2309863/ 6. Von der Maase H et al. JCO . 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068/ 7. von der Maase H et al. JCO . 2023;41(23):3881-3890. doi:10.1200/JCO.22.02763 8. Vuky J et al. . JCO . 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_05 Muscle Invasive Bladder Cancer 29:16
29:16
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי29:16![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Etymology, presentation, and work-up of bladder/urothelial cancer 2. Role of perioperative systemic therapy 3. Tri-modality therapy (bladder sparing approach) 4. Considerations for upper tract urothelial cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Bellmunt J et al. Lancet Oncol . 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8 2. Birtle AJ et al. JCO . Published online February 13, 2024. doi:10.1200/JCO.23.01659 3. Birtle A et al. Lancet . 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3 4. Bajorin DF et al. NEJM . 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/ 5. James ND et al. NEJM . 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/ 6. Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507 7. Pfister C et al. Eur Urol . 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024 8. Grossman HB et al. NEJM . 2003;349(9):859-866. doi:10.1056/NEJMOA022148/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 01_14 Ampullary Carcinoma (Mini Discussion) 10:59
10:59
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי10:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Clinical presentation and work-up 2. Intestinal and pancreatobiliary subtypes 3. Role of perioperative therapy 4. Considerations for metastatic disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Neoptolemos JP et al. JAMA . 2010;304(10):1073-1081. doi:10.1001/JAMA.2010.1275 2. Smeenk HG et al.. Ann Surg . 2007;246(5):734-740. doi:10.1097/SLA.0B013E318156EEF3 3. Chang DK , et al. J Clin Oncol . 2013;31(10):1348-1356. doi:10.1200/JCO.2012.46.8868 4. Schueneman A et al. Br J Cancer . 2015;113(1):64-68. doi:10.1038/BJC.2015.172 5. Chiorean EG et al. Journal of the National Comprehensive Cancer Network . 2023;21(7):753-782. doi:10.6004/JNCCN.2023.0034 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_04 Castrate Resistant Metastatic Prostate Cancer 24:50
24:50
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי24:50![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. On continuation of ADT and ARAT switch 2. Systemic therapy options after progression 3. Improper mandated crossover 4. PARP inhibitors in prostate cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Freedland SJ et al. NEJM . 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/ 2. de Bono J et al. NEJM . 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/ 3. Haslam A, Prasad V. Annals of Oncology . 2018;29(5):1079. doi:10.1093/ANNONC/MDY116 4. Parker C et al. NEJM . 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/ 5. Khalaf DJ et al. Lancet Oncol . 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6 6. Saad F et al.. J Natl Cancer Inst . 2004;96(11):879-882. doi:10.1093/JNCI/DJH141 7. Sartor O et al. NEJM . 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/ 8. de Wit R et al. NEJM . 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_03 Metastatic Castrate Sensitive Prostate Cancer 29:02
29:02
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי29:02![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. The chemotherapy revolution in prostate cancer 2. Role of ARATs in earlier disease states 3. Triple therapy (chemotherapy, ADT, and ARAT) 4. Considerations for frailer patients with indolent disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Hussain M et al.. J Clin Oncol . 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041 2. Smith MR et al. NEJM . 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/ 3. Fizazi K et al. Lancet . 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1 4. Sweeney CJ et al. Lancet Oncol . 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3 5. Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2 . 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4 6. Gravis G et al. Lancet Oncol . 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0 7. James ND et al. NEJM . 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/ 8. Fizazi K, et al. Lancet Oncol . 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8 9. James ND et al. Lancet . 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5 10. Gravis G et al. Lancet Oncol . 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0 11. Sweeney CJ et al. NEJM . 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\ 12. James ND et al. The Lancet . 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5 13. Fizazi K et al. NEJM . 2017;377(4):352-360. doi:10.1056/NEJMOA1704174 14. Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720 15. Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_02 Adjuvant Options for Prostate Cancer 28:41
28:41
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי28:41![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Physiology, efficacy and toxicities of androgen deprivation 2. Evidence for adjuvant intervention after definitive surgery or radiation 3. Role of abiraterone in high-risk localized prostate cancer 4. Limited evidence to support definitive salvage approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Attard G et al. Lancet . 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5 2. Xie W et al. J Clin Oncol . 2017;35(27):3097-3104. doi:10.1200/JCO.2017.73.9987 3. Bolla M et al.. NEJM . 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/ 4. Kishan AU et al. Lancet Oncol . 2022;23(2):304-316. doi:10.1016/S1470-2045(21)00705-1 5. Bolla M et al. Lancet . 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4 6. Bolla M et al. Lancet Oncol . 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0 7. Bolla M et al. NEJM . 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/ 8. Hanks GE et al. J Clin Oncol . 2003;21(21):3972-3978. doi:10.1200/JCO.2003.11.023 9. Bolla M et al. Lancet . 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4 10. Huggins C, Hodges C V. CA Cancer J Clin . 1972;22(4):293-297. doi:10.3322/CANJCLIN.22.4.232 11. Huggins C et al. Arch Surg . 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004 12. Rosenthal SA et al. J Clin Oncol . 2019;37(14):1159-1168. doi:10.1200/JCO.18.02158 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 04_01 Fundamentals of Localized Prostate Cancer 31:59
31:59
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי31:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Background and presentation of prostate Cancer 2. Evidence behind PSA screening and hallmarks of a screening test 3. Staging and risk stratification of Localized Disease 4. Management options and the ProtecT Trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.Schroder F et al. NEJM . 2009; 360 (13):1320-1328. doi: 10.1056/NEJMOA0810084/ 2. Andriole G el al. NEJM . 2009; 360 (13):1310-1319. doi: 10.1056/NEJMOA0810696/ 3. Lane J et al. Lancet . 2014; 15 (10):1109-1118. doi: 10.1016/S1470-2045(14)70361-4 4. Hamdy F et al. NEJM . 2016; 375 (15):1415-1424. doi: 10.1056/NEJMOA1606220 5. Hamdy F et al. NEJM. 2023; 388 (17):1547-1558. doi: 10.1056/NEJMOA2214122/ 6. Ilic D et al. BMJ. 2018; 362 :k3519. doi:10.1136/BMJ.K3519 7.Maurer T et al. Nat Rev Urol. 2016; 13 (4):226-235. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18
37:18
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי37:18![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Role for definitive chemotherapy and radiation 2. Controversy on induction chemotherapy 3. Considerations for nasopharyngeal cancer 4. Approach to metastatic HNSCC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Burtness B et al. J Clin Oncol . 2022;40(21):2321-2332. doi:10.1200/JCO.21.02198 2. Burtness B et al. Lancet . 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7 3. Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656 4. Gibson MK et al. JCO . 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057 5. Zhang L et al. Lancet . 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-5 6. Zhang Y et al. NEJM . 2019;381(12):1124-1135. doi:10.1056/NEJMOA1905287 7. Gau M et al. Oral Oncol . 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.015 8. GT W, et al. NEJM . 1991;324(24):1685-1690. doi:10.1056/NEJM199106133242402 9. Lacas B et al. Radiother Oncol . 2021;156:281. doi:10.1016/J.RADONC.2021.01.013 10. Bourhis et al. JCO . 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.5505 11. Gyawali B et al. Cancer Treat Rev . 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.002 12. Forastiere AA et al. J Clin Oncol . 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245 13. Posner MR et al. NEJM . 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28
23:28
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי23:28![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Anatomy, diagnostic work-up and staging 2. Field cancerization 3. Indications for adjuvant concurrent chemoradiation 4. Evidence to support weekly cisplatin with concurrent radiation Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Bernier J et al. Head Neck . 2005;27(10):843-850. doi:10.1002/HED.20279 2. Zevallos JP et al. Head Neck . 2021;43(1):108. doi:10.1002/HED.26465 3. Young A, Okuyemi OT. StatPearls . Published online January 12, 2023. Accessed October 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK563022/ 4. Kiyota N et al. J Clin Oncol . 2022;40(18):1980-1990. doi:10.1200/JCO.21.01293 5. Sharma P et al. J Clin Oncol . 2022;40(16). doi: 10.1200/JCO.2022.40.16_suppl.6004 6. Cooper JS et al. NEJM . 2004;350(19):1937-1944. doi:10.1056/NEJMOA032646 7. Bernier J et al. NEJM. 2004;350(19):1945-1952. doi:10.1056/NEJMOA032641 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
![Artwork](/static/images/128pixel.png)
1 03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40
29:40
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי29:40![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Presentation, and considerations for regional mesothelioma 2. Systemic therapy options for advanced mesothelioma 3. Corticosteroids for pemetrexed, paclitaxel and docetaxel 4. A quick review on considerations for LCNEC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Peters S et al. Ann Oncol . 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074 2. Baas P et al. Lancet . 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8 3. Vogelzang NJ et al. J Clin Oncol . 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136 4. Zalcman G, et al. Lancet . 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-6 5. Santoro A, et al. J Thorac Oncol . 2008;3(7):756-763. doi:10.1097/JTO.0B013E31817C73D6 6. Lindsay CR et al. Br J Cancer 2021;125(9):1210-1216. doi:10.1038/s41416-021-01407-9 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1. Background on SCLC 2. Approach to treatment by stage 3. Emerging discussion on prophylactic cranial irradiation 4. Brief review of basket and umbrella trials Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Trigo J et al. Lancet Oncol . 2020;21(5):645-654. doi:10.1016/S1470-2045(20)30068-1 2. O’Brien MER et al. J Clin Oncol . 2006;24(34):5441-5447. doi:10.1200/JCO.2006.06.5821 3. Rudin CM et al. J Clin Oncol . 2020;38(21):2369-2379. doi:10.1200/JCO.20.00793 4. Paz-Ares L et al. The Lancet . 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6 5. Horn L et al NEJM . 2018;379(23):2220-2229. doi:10.1056/NEJMOA1809064/ 6. Lowenbraun S et al. Cancer . 1979;44:406-413. doi:10.1002/1097-0142 7. Hochstenbag M et al.. J Neurooncol . 2000;48(3):243-248. doi:10.1023/A:1006427407281 8. Meert AP et al. BMC Cancer . 2001;1(1):1-9. doi:10.1186/1471-2407-1-5/TABLES/4 9. Fried DB et al. J Clin Oncol . 2004;22(23):4785-4793. doi:10.1200/JCO.2004.01.178 10. Pignon JP et al. 2010;327(23):1618-1624. doi:10.1056/NEJM199212033272302 11. Warde P, Payne D. J Clin Oncol . 1992;10(6):890-895. doi:10.1200/JCO.1992.10.6.890 12. Wong AT et al. J Thorac Oncol . 2016;11(2):242-248. doi:10.1016/J.JTHO.2015.10.011 13. Lu C et al. Ther Innov Regul Sci . 2021;55(6):1145. doi:10.1007/S43441-021-00315-7 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_09 Stage III NSCLC for the Medical Oncologist 27:46
27:46
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי27:46![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Refresher on T+N staging for Stage III 2. Evidence for concurrent chemoradiation 3. PACIFIC Trial 4. Encourage cessation regardless of stage of Lung Cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Ajani JA et al.. Ann Oncol . 2013;24(11):2844-2849. doi:10.1093/ANNONC/MDT339 2. Curran WJ et al. J Natl Cancer Inst . 2011;103(19):1452-1460. doi:10.1093/JNCI/DJR325 3. Vokes EE, et al. JCO . 2007;25(13):1698-1704. doi:10.1200/JCO.2006.07.3569 4. Dillman RO et al. NEJM . 1990;323(14):940-945. doi:10.1056/NEJM199010043231403 5. Daly ME et al. J CO . 2022;40(12):1356-1384. doi:10.1200/JCO.21.02528 6. Spigel DR et al. JCO . 2022;40(12):1301-1311. doi:10.1200/JCO.21.01308 7. Antonia SJ et al. NEJM . 2017;377(20):1919-1929. doi:10.1056/NEJMOA1709937 8. Senan et al. JCO . 2016;34(9):953-962. doi:10.1200/JCO.2015.64.8824 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1. Background on adjuvant EGFR therapy 2. Discussion of initial and updated results 3. Hazard Ratios and Context 4. When crossover and access limit generalizability Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.Herbst et al. JCO. 2023;41(10):1830-1840. doi: 10.1200/JCO.22.02186 2.Wu et al. NEJM. 2023;383:1711-1723. doi:10.1056/NEJMoa2027071 3. Tsuboi et al. NEJM. 2023;389(2):137-147. doi: 10.1056/NEJMoa2304594 4. West and Gyawali. JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.6752 5. Gyawali and West. JCO. 2021;39(3):175-177. doi: 10.1200/JCO.20.01762 6. Prasad. Plenary Session. “ADAURA OS Results”. Podcast episode published June 8, 2023 7. Haslan and Prasad. Ann Oncol. 2018; 29(5):1079–1081. doi: 10.1093/annonc/mdy116 8. Tannock et al. JCO. 2023;41(15):2713-2717 doi: 10.1200/JCO.23.00280 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1. Considerations with surgery, radiation, rate of relapse 2. Adjuvant chemotherapy 3. Adjuvant immune checkpoint inhibition 4. Emerging neoadjuvant trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Great summary of differences in 7th and 8th staging editions (misspoke in episode as radiopedia): https://radiologyassistant.nl/chest/lung-cancer/tnm-classification-8th-edition 1. Spicer J et al. JCO. 2023;41(16_suppl):8521-8521. doi:10.1200/JCO.2023.41.16_SUPPL.8521 2. Wakelee H et al. NEJM . Published online June 3, 2023. doi:10.1056/NEJMOA2302983 3. Forde PM et al. NEJM . 2022;386(21):1973-1985. doi:10.1056/NEJMOA2202170 4. Winton T et al. NEJM. 2005;352(25):2589-2597. doi:10.1056/NEJMOA043623 5. Stewart et al. BMJ . 1995;311(7010):899-909. doi:10.1136/BMJ.311.7010.899 6. Arriagada R et al. NEJM . 2004;350(4):351-360. doi:10.1056/NEJMOA031644 7. Felip E et al. The Lancet . 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5 8. Strauss GM et al. J Clin Oncol . 2008;26(31):5043-5051. doi:10.1200/JCO.2008.16.4855 9. Pignon JP et al. JCO . 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_06 Driver Mutations in Advanced NSCLC 34:06
34:06
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי34:06![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. EGFR inhibitors 2. ALK inhibitors 3. Less common molecular targets 4. Role of KRAS inhibitors and evidence for sotorasib Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. de Langen AJ et al. The Lancet . 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0 2. Wolf J et al. NEJM . 2020;383(10):944-957. doi:10.1056/NEJMOA2002787/ 3. Felip E et al. Annals of Oncology . 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.012 4. Cho BC et al. J Thorac Oncol . 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.005 5. Peters S et al. NEJM . 2017;377(9):829-838. doi:10.1056/NEJMOA1704795/ 6. Solomon BJ et al. JCO . 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.4794 7. Solomon BJ et al. NEJM . 2014;371(23):2167-2177. doi:10.1056/NEJMOA1408440 8. Yang JCH et al. Lancet Oncol . 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8 9. Soria JC et al. NEJM . 2018;378(2):113-125. doi:10.1056/NEJMOA1713137/ 10. Ramalingam SS et al. NEJM . 2020;382(1):41-50. doi:10.1056/NEJMOA1913662/ 11. Zhang SS et al. Lung Cancer: Targets and Therapy . 2023;14:27. doi:10.2147/LCTT.S403461 12. Olivier T et al. Transl Oncol . 2023;28:101591. doi:10.1016/J.TRANON.2022.101591 13. Papadimitrakopoulou VA, et al. Ann Oncol . 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.2100 14. Fukuoka M et al. J Clin Oncol . 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_05 NSCLC metastatic without driver mutations 31:52
31:52
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי31:52![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Evidence to support platinum doublets 2. The tale of pemetrexed 3. Immune checkpoint inhibitors alone and in combination 4. Second Line, approach in progression Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Paz-Ares L et al. Lancet Oncol . 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0 2. Hellmann MD et al. NEJM . 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231 3. Socinski MA et al. J Thorac Oncol . 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009 4. Reck M et al. NEJM . 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774 5. Paz-Ares L et al. NEJM . 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865 6. Gandhi L et al. NEJM . 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/ 7. Scagliotti G et al. Oncologist . 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232 8. Paz-Ares L et al. Lancet Oncol . 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3 9. Paz-Ares LG et al. JCO . 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102 10. Scagliotti GV et al. JCO . 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375 11. Delbaldo C et al. JAMA . 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470 12. Ardizzoni A et al. J Natl Cancer Inst . 2007;99(11):847-857. doi:10.1093/JNCI/DJK196 13. Temel JS et al. NEJM . 2010;363(8):733-742. doi:10.1056/NEJMOA1000678 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1. Presentation and Work-up 2. Staging and how to memorize staging algorithms 3. SVC Syndrome, an oncologic emergency 4. Variations by histology and molecular mutations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1. Patterns of recurrence and approach to stage IV disease 2. Immunotherapy and BRAF/MEK considerations 3. Cross trial comparisons 4. Later line and emerging therapies for advanced melanoma Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1. Atkins MB et al. J Clin Oncol . 2023;41(2):186-197. doi:10.1200/JCO.22.01763 2. Robert C et al. NEJM . 2019;381(7):626-636. doi:10.1056/NEJMOA1904059/ 3. Lebbé C et al. J Clin Oncol . 2019;37(11):867-875. doi:10.1200/JCO.18.01998 4. Wolchok JD et al. J Clin Oncol . 2022;40(2):127-137. doi:10.1200/JCO.21.02229 5. Larkin J et al. NEJM . 2015;373(1):23-34. doi:10.1056/NEJMOA1504030 6. Nathan P et al. NEJM . 2021;385(13):1196-1206. doi:10.1056/NEJMOA2103485 7. Sarnaik AA et al. J Clin Oncol . 2021;39(24):2656-2666. doi:10.1200/JCO.21.00612 8. Tawbi HA et al. NEJM . 2022;386(1):24-34. doi:10.1056/NEJMOA2109970 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1. Background, staging and work-up of regional melanoma 2. Evidence for adjuvant and neoadjuvant immunotherapy 3. Adjuvant BRAF/MEK inhibitor 4. Considerations for stage IIB/IIC disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1. Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437/ 2. Weber J et al. NEJM . 2017;377(19):1824-1835. doi:10.1056/NEJMOA1709030 3. Eggermont AMM et al. NEJM . 2018;378(19):1789-1801. doi:10.1056/NEJMOA1802357 4. Lao CD. Am Soc Clin Oncol Educ Book . 2022;42(42):1-7. doi:10.1200/EDBK_351153 5. Faries MB et al. NEJM . 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210/ 6. Morton DL et al. NEJM . 2014;370(7):599-609. doi:10.1056/NEJMOA1310460/ 7. Welch HG et al. NEJM . 2021;384(1):72-79. doi:10.1056/NEJMSB2019760/ 8. Michielin O et al. Ann Oncol . 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ411 9. Luke JJ et al. Lancet . 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1 10. Long G V et al. NEJM . 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539/ 11. Dummer R et al. NEJM . 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_01 The era of immune checkpoint inhibitors 22:59
22:59
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי22:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. History of Immunotherapy 2. Modern immune checkpoint inhibitors (ICIs) 3. Unique considerations with ICIs 4. Immune related adverse events and immortal time bias in observational studies Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1. Yadav K, Lewis RJ. JAMA . 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151 2. Holstead RG et al. Melanoma Res . 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736 3. Kartolo A et al. J Immunother . 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360 4. Dolladille C et al. JAMA Oncol . 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726 5. Mahmood SS et al. J Am Coll Cardiol . 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037 6. Coley WB. Proc R Soc Med . 1910;3(Surg Sect):1. doi:10.1177/003591571000301601 7. Larkin J et al. NEJM . 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/ 8. Wolchok JD et al. Lancet Oncol . 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1 9. Hodi FS et al. NEJM . 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/ 10. Brahmer J et al. JCO . 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_10 BRCA Positive Breast Cancer in the Clinic 21:39
21:39
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי21:39![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. BRCA 1/2 genes and relation to malignancy 2. Family history taking and identifying patients for genetic testing 3. Risk reduction strategies for breast and ovarian cancer 4. Systemic therapy considerations in BRCA positive breast cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1. Litton JK et al. NEJM . 2018;379(8):753-763. doi:10.1056/NEJMOA1802905/ 2. Geyer CE et al. Ann Oncol . 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159 3. Robson M et al. NEJM . 2017;377(6):523-533. doi:10.1056/NEJMOA1706450/ 4. Tutt ANJ et al. NEJM . 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215/ 5. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes 6. Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women 7. Chiarelli AM et al. JCO . 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.8331 8. Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_09 Triple Negative Breast Cancer 27:07
27:07
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי27:07![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Clinical considerations 2. Neoadjuvant and adjuvant regimens 3. Immunotherapy in localized and metastatic disease 4. Later line options in metastatic setting *Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive. Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1. Masuda N et al. NEJM . 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645/ 2. Zaheed M et al. Cochrane . 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/ 3. Cortes J et al. The Lancet . 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9 4. Cortes J et al. NEJM . 2022;387(3):217-226. doi:10.1056/NEJMOA2202809/ 5. Miles D et al. Ann Oncol . 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801 6. Emens LA et al. Ann Oncol . 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355 7. Schmid P et al. NEJM . 2022;386(6):556-567. doi:10.1056/NEJMOA2112651/ 8. Schmid P et al. NEJM . 2020;382(9):810-821. doi:10.1056/NEJMOA1910549/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_08 Early HER-2 positive breast cancer 25:27
25:27
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי25:27![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Role of adjuvant HER-2 Agents and during of therapy 2. Chemotherapy backbone considerations 3. Pathologic complete response 4. Neoadjuvant systemic therapy and response modified approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1.von Minckwitz G et al. NEJM . 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/ 2.von Minckwitz G et al. NEJM . 2017;377(2):122-131. doi:10.1056/NEJMOA1703643/ 3.Slamon D et al.. NEJM . 2011;365(14):1273-1283. doi:10.1056/NEJMOA0910383 4.Piccart M et al. JCO . 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204 5.Martin M et al. Lancet Oncol . 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9 6.von Minckwitz G et al. NEJM . 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/ 7.Gianni L et al. Lancet Oncol . 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-4 8.Symmans WF et al.. J Clin Oncol . 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.1010 9.Gianni L et al. Lancet Oncol . 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7 10.Gianni L et al. Lancet Oncol . 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9 11.Gilboa S et al. Eur J Cancer . 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.044 12.Tolaney SM et al. NEJM . 2015;372(2):134-141. doi:10.1056/NEJMOA1406281/ 13.Cameron D et al. Lancet . 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2 14.Earl HM et al. Lancet . 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6 15.Pivot X et al. Lancet . 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1 16.Perez EA et al. J Clin Oncol . 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730 17.Romond EH et al. NEJM . 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122/ 18.Ennis S et al.. NEJM . 2001;344(11):783-792. doi:10.1056/NEJM200103153441101 19.Hudis CA. NEJM . 2007;357(1):39-51. doi:10.1056/NEJMRA043186 20.Slamon DJ et al. Science . 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_07 HER-2 positive breast cancer: Considerations in advanced disease 25:12
25:12
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי25:12![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. Anti-HER2 agent classes 2. Cleopatra Trial 3. Later line options 4. Leptomeningeal carcinomatosis Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1. Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101 3. Baselga J et al. NEJM . 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/ 4. Swain SM et al. NEJM . 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/ 5. Verma S et al. T. NEJM . 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/ 6. Cortés J et al. NEJM . 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/ 7. Krop IE et al. Lancet Oncol . 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3 8. Murthy RK et al. NEJM . 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
T
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_06 HER-2 Low Breast Cancer and Sacutuzumab Govetecan 22:30
22:30
הפעל מאוחר יותר
הפעל מאוחר יותר
רשימות
לייק
אהבתי22:30![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
1. HER-2 Testing Algorithm 2. Trastuzumab Deruxtecan in HER-2 Low MBC 3. 2:1 Randomization, Treatment of Provider Choice 4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Some highlighted references recommended to read related to this specific episode: 1.Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738 2.Modi S et al. NEJM . 2022;387(1):9-20. doi:10.1056/NEJMOA2203690/ 3.BardiaI A et al. NEJM . 2021;384:1529-1541. doi:10.1056/NEJMOA2028485 4.Rugo H et al. JCO . Published online Aug 26, 2022 . doi:10.1200/JCO.22.01002 5.Rugo H et al. Ann Oncol . 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology Thanks to Feed Spot for recognition as one of the best oncology podcasts! https://blog.feedspot.com/oncology_podcasts/…
ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.